Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 5,940 shares at $28.44 ($169K) on 2023-01-05, disclosed to the SEC on 2023-01-09.
Open-market sale of $169k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.44 | 2,970 | $84K | 50.0% |
| 2 | $28.44 | 2,970 | $84K | 50.0% |
| Total | $28.44 avg | 5,940 | $169K | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |